Antibodies against various forms of mildly oxidized low-density lipoprotein are not associated with carotid intima-media thickness in patients with primary hyperlipidemia

Angiology

Volumn 57, Issue 5, 2006, Pages 615-622

  Tsouli, Sofia G ^a   Kiortsis, Dimitrios N ^a   Xydis, Vasilios ^a   Argyropoulou, Maria I ^a   Elisaf, Moses ^a   Tselepis, Alexandros D ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ALDEHYDE DERIVATIVE; AUTOANTIBODY; IMMUNOGLOBULIN G; LYSOPHOSPHATIDYLCHOLINE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AGE; ANTIBODY TITER; ARTERY INTIMA; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; ENZYME INACTIVATION; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPID ANALYSIS; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AUTOANTIBODIES; CAROTID ARTERIES; FEMALE; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; TUNICA INTIMA; TUNICA MEDIA;

EID: 33749850685     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319706293142     Document Type: Article

References (32)

1. Steinberg D, Parthasarathy S, Carew TE, et al: Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320:915-924, 1989.
2. Bhakdi S, Lackner KJ, Han S-R, et al: Beyond cholesterol: The enigma of atherosclerosis revisited. Thromb Haemost 91:639-645, 2004.
3. Clare K, Hardwick SJ, Carpenter KL, et al: Toxicity of oxysterols to human monocyte-macrophages. Atherosclerosis 118:67-75, 1995.
4. Kugiyama K, Kerns SA, Morrisett JD, et al: Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 344:160-162, 1990.
5. Fukumoto M, Shoji T, Emoto M, et al: Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. Arterioscler Thromb Vasc Biol 20:703-707, 2000.
6. Salonen JT, Yla-Herttuala S, Yamamoto R, et al: Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 339:883-887, 1992.
7. Maggi E, Chiesa R, Melissano G, et al: LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler Thromb 14:1892-1899, 1994.
8. 2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 3:57-68, 2002.
9. Karasawa K, Harada A, Satoh N, et al: Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res 42:93-114, 2003.
10. Liapikos ThA, Antonopoulou S, Karabina S-AP, et al: Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivated. Biochim Biophys Acta 1212:353-360, 1994.
11. Lourida E, Tsouli SG, Kiortsis DN, et al: The levels of autoantibodies against oxidised LDL in hypercholesterolemic patients are influenced by the LDL-associated PAF-acetylhydrolase activity. Atherosclerosis Suppl 5:133, 2004.
12. Cheng KS, Mikhailidis DP, Hamilton G, et al: A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. Cardiovasc Res 54:528-538, 2002.
13. Bots ML, Hoes AW, Koudstaal PJ, et al: Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study. Circulation 96:1432-1437, 1997.
14. Burke GL, Evans GW, Riley WA, et al: Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 26:386-391, 1995.
15. Hulthe J, Bokemark L, Fagerberg B: Antibodies to oxidised LDL in relation to intima-media-thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol 21:101-107, 2001.
16. Liu ML, Ylitalo K, Salonen R, et al: Circulating oxidized low-density lipoprotein and its association with carotid intima-media thickness in asymptomatic members of familial combined hyperlipidemia families. Arterioscler Thromb Vasc Biol 24:1492-1497, 2004.
17. Hulthe J, Wiklund O, Hurt-Camejo E, et al: Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A(2). Arterioscler Thromb Vasc Biol 21:269-274, 2001.
18. Iribarren C, Folsom AR, Jacobs DR Jr, et al: Association of serum vitamin levels, LDL, susceptibility to oxidation, and autoantibodies against MDA-LDL with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 17:1171-1177, 1997.
19. Frostegard J, Wu R, Lemne C, et al: Circulating oxidized low-density lipoprotein is increased in hypertension. Clin Sci (Lond) 105:615-620, 2003.
20. Wu R, de Faire U, Lemne C, et al: Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension 33:53-59, 1999.
21. Karvonen J, Paivansalo M, Kesaniemi YA, et al: Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 108:2107-2112, 2003.
22. Avogaro P, Bon GB, Cazzolato G: Presence of a modified low-density lipoprotein in humans. Arteriosclerosis 8:79-87, 1988.
23. Sevanian A, Bittolo-Bon G, Cazzolato G, et al: LDL is a lipid hydroperoxide-enriched circulating lipoprotein. J Lipid Res 38:419-428, 1997.
24. Edelstein C, Pfaffinger D, Hinman J, et al: Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem 278:52841-52847, 2003.
25. Wu R, Huang YH, Elinder LS, et al: Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL. Arterioscler Thromb Vasc Biol 18:626-630, 1998.
26. Dentan C, Tselepis AD, Chapman MJ, et al: Pefabloc, 4-[2-aminoethyl] benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase. Biochim Biophys Acta 1299:353-357, 1996.
27. Karabina S-AP, Liapikos TA, Grekas G, et al: Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein. Biochim Biophys Acta 1213:34-38, 1994.
28. Craig WY, Raytcheva SE, Poulin SE, et al: Effect of low-density lipoprotein (LDL) antigen source on an enzyme-linked immunosorbent assay for autoantibodies against oxidized LDL. Ann Clin Biochem 36:333-339, 1999.
29. Craig WY, Rawstron MW, Rundell CA, et al: Relationship between lipoprotein- and oxidation-related variables and atheroma lipid composition in subjects undergoing coronary artery bypass graft surgery. Arterioscler Thromb Vasc Biol 19:1512-1517, 1999.
30. Kiortsis DN, Tsouli S, Lourida ES, et al: Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia. Angiology 56:451-458, 2005.
31. Holvoet P, Perez G, Bernar H, et al: Stimulation with a monoclonal antibody (mAb4E4) of scavenger receptor-mediated uptake of chemically modified low-density lipoproteins by THP-1-derived macrophages enhances foam cell generation. J Clin Invest 93:89-98, 1994.
32. Ehara S, Ueda M, Naruko T, et al: Elevated levels of oxidized low-density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103:1955-1960, 2001.